thiosulfates has been researched along with Neoplasms in 22 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin." | 9.24 | Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. ( Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017) |
| "Twenty-eight patients with malignant pleural effusion received instillation of cisplatin (CDDP) into the pleural cavity to examine the pharmacokinetics and side effects of CDDP Thirteen patients received high-dose CDDP (120 mg/m2-160 mg/m2) in combination with sodium thiosulfate (STS), while 15 others received CDDP alone (80 mg/m2)." | 7.67 | [Studies on an appropriate intra thoracic administration of cisplatin and sodium thiosulfate in malignant pleural effusion]. ( Fukuoka, M; Kitajima, K; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ryu, S; Sakai, N; Takada, M; Takifuji, N, 1988) |
| "Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin." | 5.24 | Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. ( Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017) |
| "Two-route chemotherapy of cisdiamminedichloroplatinum (CDDP) and sodium thiosulfate (STS) was performed in 32 patients with peritonitis carcinomatosa, originated from 21 gastric cancers, 4 colorectal cancers, 3 pancreatic cancers, 2 leiomyosarcomas of small intestine, one ovarian cancer and one bile duct cancer." | 3.67 | [Clinical efficacy of two-route chemotherapy with CDDP and STS in patients with peritonitis carcinomatosa]. ( Hirao, E; Kobayashi, M; Kuwahara, A; Nakashima, K; Saito, T; Shigemitsu, Y, 1989) |
| "Twenty-eight patients with malignant pleural effusion received instillation of cisplatin (CDDP) into the pleural cavity to examine the pharmacokinetics and side effects of CDDP Thirteen patients received high-dose CDDP (120 mg/m2-160 mg/m2) in combination with sodium thiosulfate (STS), while 15 others received CDDP alone (80 mg/m2)." | 3.67 | [Studies on an appropriate intra thoracic administration of cisplatin and sodium thiosulfate in malignant pleural effusion]. ( Fukuoka, M; Kitajima, K; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ryu, S; Sakai, N; Takada, M; Takifuji, N, 1988) |
| " Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment." | 2.94 | Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. ( Hu, QY; Keilty, J; Kropp, J; McCarthy, R; Ren, Y; Shi, F; Soglia, J; Viglietta, V; Weber, P; Wolff, H, 2020) |
| "Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event." | 2.66 | Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. ( Brock, PR; Cabral, S; Chang, KW; Dupuis, LL; Epelman, S; Freyer, DR; Knight, K; Mills, D; Phillips, R; Potter, E; Risby, D; Robinson, PD; Simpkin, P; Sullivan, M; Sung, L, 2020) |
| "Nephrotoxicity is a relatively common and potentially serious adverse effect of treatment with certain cytotoxic drugs (especially ifosfamide)." | 2.39 | Strategies to prevent nephrotoxicity of anticancer drugs. ( Skinner, R, 1995) |
| "The Children's Oncology Group (COG) Cancer Control and Supportive Care Neurotoxicity Subcommittee therefore conducted a survey of providers at COG institutions to determine perspectives on pediatric otoprotection practices and research surrounding three major themes: (1) prevalence of routine use of STS with cisplatin-based regimens, (2) application of audiometry to cisplatin therapy, and (3) preferred modalities for otoprotection research." | 1.56 | Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. ( Dvorak, CC; Esbenshade, AJ; Freyer, DR; Hardy, KK; Orgel, E; Thomas, SM; Ullrich, NJ, 2020) |
| "Calciphylaxis is associated with a high mortality rate." | 1.43 | Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. ( Albright, RC; Bridges, AD; Claus, PL; Davis, MD; Dillon, JJ; El-Azhary, RA; El-Zoghby, ZM; Hickson, LJ; Kumar, R; McBane, RD; McCarthy, JT; McCarthy-Fruin, KA; McEvoy, MT; Patzelt, MT; Pittelkow, MR; Weaver, AL; Wetter, DA; Williams, AW, 2016) |
| "Sodium thiosulfate kinetics were studied in eight subjects, six of whom were given the drug as a cisplatin neutralizer." | 1.27 | Kinetics of sodium thiosulfate, a cisplatin neutralizer. ( Howell, SB; Koziol, JA; Shea, M, 1984) |
| "Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage." | 1.27 | High-dose cisplatin with sodium thiosulfate protection. ( Andrews, PA; Felthouse, RD; Howell, SB; Markman, M; Murphy, MP; Pfeifle, CE; Woliver, TB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (45.45) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Freyer, DR | 4 |
| Brock, PR | 1 |
| Chang, KW | 1 |
| Dupuis, LL | 1 |
| Epelman, S | 1 |
| Knight, K | 3 |
| Mills, D | 1 |
| Phillips, R | 1 |
| Potter, E | 1 |
| Risby, D | 1 |
| Simpkin, P | 1 |
| Sullivan, M | 1 |
| Cabral, S | 2 |
| Robinson, PD | 2 |
| Sung, L | 3 |
| Viglietta, V | 1 |
| Shi, F | 1 |
| Hu, QY | 1 |
| Ren, Y | 1 |
| Keilty, J | 1 |
| Wolff, H | 1 |
| McCarthy, R | 1 |
| Kropp, J | 1 |
| Weber, P | 1 |
| Soglia, J | 1 |
| Navarro-Ruiz, NE | 1 |
| Orgel, E | 1 |
| Ullrich, NJ | 1 |
| Hardy, KK | 1 |
| Thomas, SM | 1 |
| Dvorak, CC | 1 |
| Esbenshade, AJ | 1 |
| Brock, P | 1 |
| Reaman, G | 1 |
| Boulanger, J | 1 |
| Ducharme, A | 1 |
| Dufour, A | 1 |
| Fortier, S | 1 |
| Almanric, K | 1 |
| McCarthy, JT | 1 |
| El-Azhary, RA | 1 |
| Patzelt, MT | 1 |
| Weaver, AL | 1 |
| Albright, RC | 1 |
| Bridges, AD | 1 |
| Claus, PL | 1 |
| Davis, MD | 1 |
| Dillon, JJ | 1 |
| El-Zoghby, ZM | 1 |
| Hickson, LJ | 1 |
| Kumar, R | 1 |
| McBane, RD | 1 |
| McCarthy-Fruin, KA | 1 |
| McEvoy, MT | 1 |
| Pittelkow, MR | 1 |
| Wetter, DA | 1 |
| Williams, AW | 1 |
| Chen, L | 1 |
| Krailo, MD | 1 |
| Villaluna, D | 1 |
| Bliss, B | 1 |
| Pollock, BH | 1 |
| Ramdas, J | 1 |
| Lange, B | 1 |
| Van Hoff, D | 1 |
| VanSoelen, ML | 1 |
| Wiernikowski, J | 1 |
| Neuwelt, EA | 1 |
| JAFFE, WG | 1 |
| PAOLINO, W | 1 |
| GAVOSTO, F | 1 |
| SCHULTZ, PE | 1 |
| BONUS, RL | 1 |
| SALKIN, MS | 1 |
| SCANLON, EF | 1 |
| LAWRENCE, W | 1 |
| TAYAO, MS | 1 |
| MAHAJAN, RD | 1 |
| PAGE, R | 1 |
| MILLER, DG | 1 |
| CLAPP, P | 1 |
| OWENS, G | 1 |
| HATIBOGLU, I | 1 |
| Crabb, C | 1 |
| Tsuboi, S | 1 |
| Kajiwara, T | 1 |
| Inoue, H | 1 |
| Abe, T | 1 |
| Kamata, F | 1 |
| Shea, M | 1 |
| Koziol, JA | 1 |
| Howell, SB | 2 |
| Skinner, R | 1 |
| Brillet, G | 1 |
| Deray, G | 1 |
| Bunker, D | 1 |
| Ben Hmida, M | 1 |
| Baumelou, A | 1 |
| Jacobs, C | 1 |
| Markman, M | 2 |
| D'Acquisto, R | 1 |
| Iannotti, N | 1 |
| Kris, M | 1 |
| Hakes, T | 1 |
| Bajorin, D | 1 |
| Bosl, G | 1 |
| Reichman, B | 1 |
| Casper, E | 1 |
| Magill, G | 1 |
| Kuwahara, A | 1 |
| Saito, T | 1 |
| Nakashima, K | 1 |
| Shigemitsu, Y | 1 |
| Hirao, E | 1 |
| Kobayashi, M | 1 |
| Kitajima, K | 1 |
| Fukuoka, M | 1 |
| Kusunoki, Y | 1 |
| Negoro, S | 1 |
| Takada, M | 1 |
| Matsui, K | 1 |
| Sakai, N | 1 |
| Ryu, S | 1 |
| Takifuji, N | 1 |
| Masuda, N | 1 |
| Pfeifle, CE | 1 |
| Felthouse, RD | 1 |
| Woliver, TB | 1 |
| Andrews, PA | 1 |
| Murphy, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons[NCT04478292] | Phase 3 | 330 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Effects of Human Amniotic Mesenchymal Stem Cells (hAMSCs) on Wound Healing in Uremic Calciphylaxis Patients: an Open Label Single Arm Study[NCT04592640] | 7 participants (Anticipated) | Interventional | 2018-09-17 | Active, not recruiting | |||
| A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children[NCT00716976] | Phase 3 | 131 participants (Actual) | Interventional | 2008-06-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in hearing threshold (post-pre) at 1000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | -0.676 |
| Observation Arm | -0.319 |
Mean change in hearing threshold (post-pre) at 2000 hz (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | -1.18 |
| Observation Arm | 0.638 |
Mean change in hearing threshold (post-pre) at 4000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 1.05 |
| Observation Arm | 9.58 |
Mean change in hearing threshold (post-pre) at 500 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | -1.45 |
| Observation Arm | -1.11 |
Mean change in hearing threshold (post-pre) at 8000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Decibels (Mean) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 9.73 |
| Observation Arm | 17.0 |
Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description. (NCT00716976)
Timeframe: 4 years after enrollment
| Intervention | Percentage probability (Number) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 53.7 |
| Observation Arm | 61.4 |
Hearing loss defined by comparing hearing sensitivity at follow up evaluation relative to baseline measurements using ASHA criteria. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin
| Intervention | Patients (Number) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 14 |
| Observation Arm | 31 |
Proportion of patients alive free at 4 years following enrollment. See OS outcome measure description. (NCT00716976)
Timeframe: 4 Years after enrollment
| Intervention | Percentage probability (Number) |
|---|---|
| STS Arm (Sodium Thiosulfate Treatment) | 69.6 |
| Observation Arm | 82.0 |
6 reviews available for thiosulfates and Neoplasms
| Article | Year |
|---|---|
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Topics: Adolescent; Antineoplastic Agents; Child; Cisplatin; Female; Hearing Loss; Humans; Male; Neoplasms; | 2020 |
Prevention of Platinum-Induced Hearing Loss in Children with Cancer.
Topics: Amifostine; Humans; Neoplasms; Ototoxicity; Platinum; Practice Guidelines as Topic; Thiosulfates | 2020 |
Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Topics: Acetylcysteine; Adolescent; Amifostine; Anti-Inflammatory Agents; Antineoplastic Agents; Chelating A | 2019 |
Management of the extravasation of anti-neoplastic agents.
Topics: Antineoplastic Agents; Catheterization, Central Venous; Catheterization, Peripheral; Dexrazoxane; Di | 2015 |
Strategies to prevent nephrotoxicity of anticancer drugs.
Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human | 1995 |
[Can cisplatin renal toxicity be prevented?].
Topics: Calcium Channel Blockers; Cisplatin; Diuretics; Humans; Kidney Diseases; Neoplasms; Thiosulfates | 1991 |
3 trials available for thiosulfates and Neoplasms
13 other studies available for thiosulfates and Neoplasms
| Article | Year |
|---|---|
Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.
Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Cisplatin; Follow-Up Studies; Hearing Loss; | 2020 |
Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis.
Topics: Adult; Aged; Aged, 80 and over; Calciphylaxis; Debridement; Diabetes Mellitus; Female; Glomerular Fi | 2016 |
The influence of sodium thiosulfate on experimental tumor induction.
Topics: Adenoma; Animals; Choline; Choline Deficiency; Humans; Liver; Liver Neoplasms; Neoplasms; Neoplasms, | 1948 |
[Unusual effects of administration of sodium thiosulfate or of cysteine on the clinical picture and metabolism of subjects with diffuse neoplasms].
Topics: Cysteine; Humans; Neoplasms; Thiosulfates | 1953 |
The in vivo and in vitro neutralization of nitrogen mustard for use in cancer chemotherapy perfusion.
Topics: Humans; In Vitro Techniques; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Perfusion; Thio | 1962 |
SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY.
Topics: Biomedical Research; Carcinoma; Carcinoma, Squamous Cell; Dogs; Geriatrics; Infusions, Parenteral; I | 1964 |
Clinical evaluation of sodium thisulfate as a systemic neutralizer of nitrogen mustard: report of 12 patients.
Topics: Humans; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Sodium; Thiosulfates | 1961 |
Revisiting the Bhopal tragedy.
Topics: Academies and Institutes; Accidents, Occupational; Antidotes; Biomedical Research; Chemical Industry | 2004 |
[Studies on the administration methods of antitumor agents. (3). Massive shock administration of mitomycin C].
Topics: Adult; Aged; Animals; Female; Humans; Injections, Intravenous; Male; Mice; Middle Aged; Mitomycins; | 1967 |
Kinetics of sodium thiosulfate, a cisplatin neutralizer.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Cisplatin; Female; Humans; Infusions, Parenteral; | 1984 |
[Clinical efficacy of two-route chemotherapy with CDDP and STS in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Fe | 1989 |
[Studies on an appropriate intra thoracic administration of cisplatin and sodium thiosulfate in malignant pleural effusion].
Topics: Aged; Cisplatin; Drug Administration Routes; Female; Humans; Male; Middle Aged; Neoplasms; Pleural E | 1988 |
High-dose cisplatin with sodium thiosulfate protection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interaction | 1985 |